Axcella Therapeutics (AXLA) – Long COVID Phase 2b/3 Trial Changes The AXA1125 Outlook

0 min read

Wednesday, January 25, 2023

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to restore cellular homeostasis in multiple key biological pathways and improve cellular energetic efficiency. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID and non-alcoholic steatohepatitis (NASH), and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Regulators Agree With Axcella’s Plan For A Phase 2b/3 Clinical Trial. Axcella Heath announced that US and UK regulators have agreed to a plan for a global Phase 2b/3 study of AXA1125 in Long COVID-19 patients. An IND has been submitted to the FDA for trials in the US, and agreement from the UK regulators has been received.  The Phase 2b/3 trial will include other countries to support worldwide approvals.  We see this as an important milestone for AXA1125 and the future of the company.

The Trial Announcement Reduces Uncertainty Around AXA1125.  As discussed in our Research Note on August 3, results from the Phase 2a trial in Long COVID showed a significant improvement in the physical fatigue, mental fatigue, and the 6-minute walk test. In December 2022, the company restructured to preserve cash, raising uncertainty about further development for the drug. The announcement of the Phase 2b/3 IND submission provides a development plan, allowing investors to assess timeframes and progress toward the market.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 


No comments yet...

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.